Cargando…

The optimal neoadjuvant regimen for nonsmall cell lung cancer: A meta-analysis

To compare the efficacy and complications of different neoadjuvant to determine the optimal regimens for nonsmall cell lung cancer (NSCLC) patients. METHODS: A systematic search of the Web of Science, and PubMed databases was conducted through June 3, 2021, reporting a comparison of chemotherapy, ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi, Zhao, Chong, Lu, Qiuliang, Hu, Yirong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410656/ https://www.ncbi.nlm.nih.gov/pubmed/36042672 http://dx.doi.org/10.1097/MD.0000000000030159

Ejemplares similares

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
por: Tfayli, Arafat, et al.
Publicado: (2020)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis
por: Chen, Yujia, et al.
Publicado: (2023)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

A meta‐analysis: microRNAs’ prognostic function in patients with nonsmall cell lung cancer
por: Yu, Na, et al.
Publicado: (2017)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?
por: Cai, Jing‐Sheng, et al.
Publicado: (2021)

Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence
por: Kaur, Harpreet, et al.
Publicado: (2016)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis
por: Li, Kejun, et al.
Publicado: (2022)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis: Erratum
Publicado: (2015)

Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review
por: Xu, Xiao-Ling, et al.
Publicado: (2016)

The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis
por: Liu, Jing, et al.
Publicado: (2020)

MicroRNAs in sputum specimen as noninvasive biomarkers for the diagnosis of nonsmall cell lung cancer: An updated meta-analysis
por: Zhang, Xiaoyun, et al.
Publicado: (2019)

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
por: Gomez, Daniel R., et al.
Publicado: (2012)

Radiofrequency Ablation for Early-Stage Nonsmall Cell Lung Cancer
por: Hiraki, Takao, et al.
Publicado: (2014)

Pattern of bone metastasis in patients with nonsmall cell lung cancer
por: Miyazaki, Kunihiko, et al.
Publicado: (2018)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
por: Ye, Liang, et al.
Publicado: (2017)

Disparate outcomes in nonsmall cell lung cancer by immigration status
por: Chau, Brittney, et al.
Publicado: (2021)

How to handle oligometastatic disease in nonsmall cell lung cancer
por: Eichhorn, Florian, et al.
Publicado: (2021)

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
por: Crinò, Lucio, et al.
Publicado: (2014)

New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021)

A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer
por: Zhu, Jianfei, et al.
Publicado: (2022)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

The Core Mechanism of Yiqi Yangjing Decoction Inhibiting Nonsmall-Cell Lung Cancer
por: Yi, Kaiyan, et al.
Publicado: (2022)

Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer
por: Hu, Ai-Min, et al.
Publicado: (2018)

Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer
por: Dang, Yutao, et al.
Publicado: (2020)

The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
por: Xu, Weiru, et al.
Publicado: (2014)

Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: He, Jiaxi, et al.
Publicado: (2015)

BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis
por: Su, Wenxia, et al.
Publicado: (2019)

The Prognostic Significance of the Histological Types in Patients With Nonsmall Cell Lung Cancer ≤2 cm
por: Hao, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkt3mm7o9ouhg66vq1vhq57e7k